pre-IPO PHARMA

COMPANY OVERVIEW

PellePharm, a BridgeBio company, is committed to targeting rare genetic dermatological conditions, including Gorlin Syndrome and Basal Cell Carcinomas (BCCs), at the source. PellePharm is committed to improving the quality of life for those suffering from Gorlin Syndrome and BCCs by providing an easy-to-use topical solution that eliminates the need for regular, painful surgeries. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor.


LOCATION

  • San Francisco, CA, USA

  • THERAPEUTIC AREAS

  • Dermatology
  • Rare Diseases

  • WEBSITE

    https://www.pellepharm.com/


    CAREER WEBSITE

    https://pellepharm.com/join-us/


    SOCIAL MEDIA


    INVESTORS

    aisling-capital bridgebio-pharma ecor1-capital


    PRESS RELEASES


    Oct 29, 2020

    PellePharm to Highlight Clinical Programs at the 29th Congress of the European Academy of Dermatology and Venereology


    Jan 8, 2020

    PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma


    Dec 2, 2019

    PellePharm Completes Enrollment of Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome


    Apr 1, 2019

    PellePharm Initiates Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome


    Jan 31, 2019

    Phyton Biotech Partners with PellePharm to Develop Renewable Supply of Cyclopamine for Investigational Topical Cancer Therapy


    For More Press Releases


    Google Analytics Alternative